Is the AstraZeneca share price a FTSE 100 bargain?

G A Chester discusses the investment case for FTSE 100 (INDEXFTSE:UKX) giant AstraZeneca plc (LON:AZN) and a small-cap pharma firm with news today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price has retreated from a high of 6,525p made as recently as 21 March. Currently trading at not much above 6,000p, could this dip be an opportunity to snap up some shares?

Here, I’ll discuss the valuation and prospects of the FTSE 100 giant. I’ll also look at small-cap peer Alliance Pharma (LSE: APH), which released a trading update this morning.

Contrasting business models

Astra and Alliance may be in the same industry, but they have very different business models. The £80bn-cap Footsie group is a traditional, research-led big pharma business, trusting in heavy research investment to unearth its share of blockbuster drugs.

By contrast, £400m-cap AIM-listed Alliance licences or acquires pharmaceutical and consumer healthcare products — it has a portfolio of over 90 — at prices on which it believes it can make a good return.

Growth at a reasonable price

In today’s update ahead of its AGM, Alliance said it continues to trade well, with overall performance in line with expectations. It added: “We look ahead to the remainder of 2019 with confidence.”

City analysts are forecasting earnings per share (EPS) growth of 11% to 5.03p this year (following 12% growth last year). At a share price of 76.5p, this gives a forward price-to-earnings (P/E) ratio of 15.2.

I believe this proven, relatively low-risk business merits the P/E rating, and offers growth at a reasonable price. I think fairly consistent annual double-digit EPS growth is a credible prospect, supplemented by dividend growth from the 1.6p forecast for this year (prospective yield of 2.1%). As such, I rate the stock a ‘buy’.

Return to growth

Meanwhile, AstraZeneca has struggled for growth for many years, a string of patent expiries on some of its biggest blockbuster drugs taking a heavy toll. Revenues from these products fell off a cliff when exposed to competition from cheap generics.

It’s taken a long time for the company to rebuild its pipeline, and for new products with blockbuster potential to come through. However, that pipeline is now looking strong, and revenues and profits are forecast to start growing again.

The company has guided for core EPS of between $3.50 and $3.70 this year which, at the midpoint, would be 4% ahead of last year. At the current share price of 6,030p, and at current exchange rates, the midpoint $3.60 EPS equates to 285p and a P/E of 21.2. A running dividend of $2.80 (222p) gives a yield of 3.7%.

Heydays gone for good?

Despite the prospect of a return to growth in coming years, I reckon Astra’s P/E of 21.2 is far too optimistic. I think the heydays for the big pharma of earlier this century — when companies were making a terrific profit margin and return on capital employed — are gone for good.

There are two principal reasons behind my belief. First, every breakthrough drug sets the bar higher for the next. I think this is manifested in endemic falling returns on R&D investment in the industry. Secondly, as my colleague Stepan Lavrouk recently pointed out, public health bodies, such as the US Food and Drug Administration, are “increasingly seen to favour lower-cost alternatives to some of the more expensive options.”

For these reasons, I’m inclined to avoid Astra on its current P/E. There’s growth to come, for sure, but I don’t think it’s growth at a reasonable price right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Alliance Pharma and AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »